FeesSafety
Pluang+

TransDigm reports Q4 sales up 23%, EPS up 33%, and raises 2027 outlook with 14% sales growth forecast.

Company Fundamentals
10 Nov 2026, 13:30 WIB
PRNewsWire
View Source
Bullish
TransDigm reports Q4 sales up 23%, EPS up 33%, and raises 2027 outlook with 14% sales growth forecast.

TransDigm Group reported a 23% increase in net sales to $2.99 billion and a 33% rise in earnings per share to $10.33 for Q4 2026, driven by organic growth and acquisitions. Despite a slight net income decline due to higher interest and tax expenses, adjusted net income rose 12%. The company completed a $1.07 billion acquisition and issued $3 billion in notes to refinance debt. For fiscal 2027, TransDigm projects 14% sales growth and a 15% increase in adjusted earnings per share, reflecting confidence in continued market expansion.

TransDigm Group's fiscal 2026 fourth quarter saw net sales rise 23% to $2.99 billion and earnings per share increase 33% to $10.33. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: among 135 priced US Industrials stocks, 50 rose and 69 fell. Notable movers include GFL Environmental Inc. down 16.02% at USD 38.53, Rocket Lab USA Inc. down 6.57% at USD 54.99 with 79% sell order activity, and Archer Aviation Inc. down 3.43% at USD 4.64 with a typical hold time of 21 days.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
59 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
59 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
59 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
59 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App